- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00403598
Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders
Study Overview
Status
Conditions
Detailed Description
Osteoporosis is an important and costly health issue. The diagnosis of the disease is based on measurement of bone mineral density or the occurrence of characteristic fractures. Currently it is not possible to predict fractures in individual patients, and the ability to monitor the response to treatment is limited as well.
We have synthesized and characterized a novel photoreactive Ca2+-analog reagent, Azido ruthenium (AzRu) that binds covalently to Ca2+-binding sites in proteins. The specificity of AzRu for Ca2+-binding proteins, its photoactivation and its radioactive labeling pave the way for a wide use of AzRu as a powerful tool to assess Ca2+-dependent cellular processes, both in vitro and in vivo. Using radiolabeled AzRu, it will be possible to identify Ca2+-binding proteins in a biological sample such as whole cell, isolated mitochondria, ER or other protein containing fractions. Protein bound [103Ru]AzRu in biological sample can be separated by SDS gel electrophoresis, followed by Coomassie staining and exposure of the dried gel to X-ray film (autoradiography). This allows the identification of the [103Ru] radiolabeled proteins. The labeled protein bands can be cut from the gel and subjected to MALADI-TOF analysis and the identity of the protein can be determined by a sequence homology search.
These would allow detection of Ca2+-binding proteins in the serum of various diseases and disorders, potentially leading to identification of novel biomarkers for disease diagnostics.
We would like to use blood samples to carry out the procedure described above for identification of Ca2+ binding proteins appearing or their level is increased in disease or under pathogenic conditions. Since Ca2+ binding proteins play an important role in bone metabolism, we chose to test their occurrence in the serum of patients with osteoporosis and other metabolic bone diseases.
Study Type
Contacts and Locations
Study Contact
- Name: Iris Vered, MD
- Phone Number: 972-3-5303103
- Email: iris.vered@sheba.health.gov.il
Study Contact Backup
- Name: Varda Shoshan-Barmatz, Ph.D
- Phone Number: 972-8-6461336
- Email: vardasb@bgu.ac.il
Study Locations
-
-
-
Ramat Gan, Israel, 52621
- Sheba Medical Center, Tel Hashomer
-
Principal Investigator:
- Iris Vered, M.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of a metabolic bone disorder
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Iris Vered, M.D, Sheba Medical Center, Tel Hashomer
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHEBA-06-4372-IV-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parathyroid Diseases
-
Shandong Linglong Yingcheng HospitalRecruitingIndocyanine Green | Total Thyroidectomy | Parathyroid Function Low Adverse Event | Parathyroid Glands--DiseasesChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPrimary Hyperparathyroidism | Parathyroid Gland Carcinoma | Parathyroid Gland Adenoma | Parathyroid Gland Atypical AdenomaUnited States
-
M.D. Anderson Cancer CenterCompletedParathyroid Carcinoma | Parathyroid NeoplasmUnited States
-
Washington University School of MedicineActive, not recruiting
-
M.D. Anderson Cancer CenterRecruiting
-
University of ArkansasCompletedParathyroid DiseaseUnited States
-
University of ArkansasCompletedParathyroid DiseaseUnited States
-
Oxford University Hospitals NHS TrustTheraclionTerminatedParathyroid AdenomasUnited Kingdom
-
TheraclionCompletedPrimary Parathyroid AdenomasFrance
-
M.D. Anderson Cancer CenterWithdrawnParathyroid Disease